Skip to main content
Caplight Logo









BioMind

BioMind

Private
SingaporeHealthcare & Life Scienceshttps://biomind.ai/

Last Round

Series B

Aug 1, 2021

Est. Valuation

$500M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

BioMind is a healthtech company that develops artificial intelligence-based medical imaging diagnostic software to assist physicians in identifying and analyzing medical conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Medical Imaging, Healthcare Analytics, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

medical AIdiagnostic support softwareAI-assisted diagnosismedical imaging analysissoftware as a medical deviceSaMDradiology AIdeep learningclinical decision supporthealthcare analyticsmedtechdrug discoverygenomic data analysisPACS integrationprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioMind Comparables

Compare BioMind with similar companies based on industry and business-model similarity.

BioMind comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Careverse
84%
Qure.ai
81%
Brainomix
81%

BioMind Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 1, 2021
Series A ExtensionNov 1, 2020
Series AAug 1, 2019
AngelNov 1, 2018

BioMind Investors

Notable investors and investment history

BioMind investors
InvestorRounds
Power CapitalSeries A Extension
China Science and Technology Industry Investment ManagementSeries B
Tianfeng Tianrui InvestmentSeries A Extension
Bosera Asset ManagementSeries A Extension
Green Harbor InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 264% MoM, reaching 3K.

  • Oct 30, 2024

    Monthly visitors grew 153% MoM.

BioMind Filings

Explore SEC and related filing metadata, where available.

BioMind filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BioMind's valuation, stock price, and market status.

Is BioMind a public or private company?

BioMind is a private company.

What is the current stock price of BioMind?

BioMind is a private company with no public stock price. No recent secondary market data is available.

How much is BioMind worth (valuation)?

BioMind's valuation is estimated at $500.0M based on funding round data.

Can I buy BioMind stock?

BioMind shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BioMind's last funding round?

BioMind's most recent funding round was Series B on August 1, 2019.

Who are the main investors in BioMind?

Key investors in BioMind include Power Capital, China Science and Technology Industry Investment Management, Tianfeng Tianrui Investment, Bosera Asset Management, Green Harbor Investment.

Will BioMind IPO soon?

No public IPO plans have been announced for BioMind.

How can I track BioMind secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioMind's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range5
Year Founded2017
Last FundingAug 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?